Overview

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated microsphere (eMS) formulation
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Crizotinib